Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Steven Edmundowicz MD, MASGE
Steven A. Edmundowicz MD, MASGE Associate Editor
Gail Hecht MD
Gail Hecht MD Editor-in-Chief
Scott Cotler MD
Scott J. Cotler MD Associate Editor
See All Experts
featured
Published in Gastroenterology

Journal Scan / Research · October 13, 2021

Saroglitazar for Treatment of NAFLD

Hepatology (Baltimore, Md.)

 

 Save  Recommend
 Share

Additional Info

Hepatology (Baltimore, Md.)
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial
Hepatology 2021 Oct 01;74(4)1809-1824, S Gawrieh, M Noureddin, N Loo, R Mohseni, V Awasty, K Cusi, KV Kowdley, M Lai, E Schiff, D Parmar, P Patel, N Chalasani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated